Neuroblastoma: Can lessons from the past help to improve the future?
Article Sidebar
Main Article Content
Abstract
Background. The outcome of patients with neuroblastoma in South Africa has always been very poor. We conducted a retrospective study in one state-funded paediatric oncology unit (POU), to describe the clinical course, evaluate prognostic factors and report outcomes of patients with neuroblastoma.
Methods. We analysed routine data from one POU, gathered between 1993 and 2018. Kaplan-Meier curves were used to illustrate 2-year survival rates and to evaluate possible prognostic factors.
Results. Data from 87 patients were included and analysed. The median age was 41 months. The majority of the patients presented with stage 4 disease (77%). The most common presenting symptoms were bone pain, loss of weight, and abdominal distention. Chemotherapy was administered to 74 patients, and only 5 patients (6%) received palliative chemotherapy as first-line treatment. Only 18 of the 87 patients had surgery (21%) and 13 of 87 had radiation (15%), while 10 patients received palliative radioactive iodine (131I-miBG) therapy. Patients with ferritin levels >120 ng/dL did not have a poorer outcome, and those with a raised lactate dehydrogenase (LDH) level displayed a shorter survival time but it was not statistically significant. The 2-year overall survival was 24% for the whole cohort and 16% for the stage 4 patients at diagnosis.
Conclusion. Neuroblastoma is a disease with a dismal outcome in our POU, mostly as a result of late presentation. To improve prognosis the focus should be on recognising danger signs to ensure early diagnosis and referral. We recommend adding danger signs for childhood cancer to the Integrated Management of Childhood Illness (IMCI) strategy in an attempt to improve early recognition and diagnosis of childhood cancer.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The SAJCH is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
References
Hanahan D, Weinberg RA, Francisco S. The hallmarks of cancer. Cell 2000;100:57-70.
Moten A, Schafer D, Ferrari M. Improving cancer care in developing settings. Glob J Health Sci 2014;4(1):1-5.
Bray F, Ferlay J, Soerjomataram I. Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424. https://doi.org/10.3322/caac.21492
National Cancer Institute. Childhood and adolescent cancers. NIH 2021.
https://www.cancer.gov/types/childhood-cancers/child-adolescent-cancers-
fact-sheet (accessed 11 April 2023).
Hallett A, Traunecker H. A review and update on neuroblastoma. Paediatr
Child Health 2012;22(3):103-107. https://doi.org/10.1016/j.paed.2011.08.005 6. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010;362(23):2202.
https://doi.org/10.1056/NEJMra0804577
Hesseling PB, Ankone K, Wessels G, Schneider JW, du Plessis L, Moore S. Neuroblastoma in southern Africa: Epidemiological features, prognostic factors and outcome. Ann Trop Paediatr 1999;19(4):357-363.
Stefan DC, Stones DK, Wainwright RD, et al. Childhood cancer incidence in South Africa, 1987 - 2007. S Afr Med J 2015;105(11):939-947. https://doi. org/10.7196/SAMJ.2015.v105i11.9780
Stones DK, de Bruin GP, Esterhuizen TM, Stefan DC. Childhood cancer survival rates in two South African units. S Afr Med J 2014;104(7):501-504. https://doi.org/10.7196/samj.7882
Hadley GP, van Heerden J. High-risk neuroblastoma in a sub-Saharan African country: Telling it like it is. Trop Doct 2017;47(4):370-374. https://doi. org/10.1177/0049475517704363
Evans AE, D’angio GJ, Propert K, Anderson J, Hann HL. Prognostic factors in neuroblastoma. Cancer 1987;59(11):1853-1859.
Bolkar ST, Ghadge MS, Raste AS. Biochemical parameters in neuroblastoma. Indian J Clin Biochem 2008;23(3):293-295.
Cangemi G, Reggiardo G, Barco S, et al. Prognostic value of ferritin, neuron- specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma. Oncol Targets Ther 2012;5:417-423.
Van Heerden J, Hendricks M, Geel J, et al. Overall survival for neuroblastoma in South Africa between 2000 and 2014. Pediatr Blood Cancer 2019;66(11):1- 12. https://doi.org/10.1002/pbc.27944
Hartley P, Daubenton JD. Curing cancer in children – early recognition and appropriate treatment are the key. S Afr Med J 2001;91(1):40-42.
Geel JA, Stevenson BT, Jennings RB, et al. Enough is not enough: Medical students’ knowledge of early warning signs of childhood cancer. S Afr Med J 2017;107(7):585-589. https://doi.org/10.7196/SAMJ.2017.v107i7.12211
HendricksM.Prioritiesinchildhoodcancer.SAfrJChildHealth2007;1(3):96-97. 18. Poyiadjis S, Wainwright L, Naidu G, et al. Warning signs for cancer in children
in a developing country. MPO 2000;324:414.
Haupt R, Garaventa A, Gambini C, et al. Improved survival of children with
neuroblastoma between 1979 and 2005: A report of the Italian neuroblastoma
registry. J Clin Oncol 2010;28(14):2331-2338.
Shroeder H, Wacher J, Larsson H, et al. Unchanged incidence and increased
survival in children with neuroblastoma in Denmark 1981-2000: A population-
based study. Br J Cancer 2009;100:853-857.
Aydn GB, Kutluk MT, Yalçn B, et al. Neuroblastoma in Turkish children:
Experience of a single center. J Pediatr Hematol Oncol 2009;31(7):471-480. 22. Kitonyi GW, Macharia WM, Mwanda OW, Pamnani R. Clinico-pathologic characteristics and treatment outcomes in children with neuroblastoma at the
Kenyatta National Hospital, Nairobi. East Afr Med J 2009;86(12 Suppl):39-46. 23. Parikh NS, Howard S, Chantada G, et al. SIOP-PODC Adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer 2015;62(8):1305-1316. https://
doi.org/10.1002/pbc.25501